Why We Invested in Resilient Lifescience — Preventing Opioid Overdose

1 min read

Excited to announce our investment in Resilient Lifescience, which is taking on the opioid epidemic by developing a wearable system to detect and automatically reverse overdoses. Tau Ventures is an AI-first fund in Silicon Valley investing primarily in seed and we occasionally take earlier or later bets when we see immense promise. We are also investing in US / Canada but in exceptional cases will consider a deal outside. Resilient was founded in 2022 in Pittsburgh and impressed us with (1) a strong need, (2) building an execution-focused team, and (3) their business strategy. 1) The Need The opioid crisis…...

This article is free to read

Login to read the full article


OR

By subscribing to our main site, you will also be subscribed to DDIntel - our regular letter showcasing our featured articles and applications.

Amit Garg I have been in Silicon Valley for 20 years -- at Samsung NEXT Ventures, running my own startup (as of May 2019 a series D that has raised $120M and valued at $450M), at Norwest Ventures, and doing product and analytics at Google. My academic training is BS in computer science and MS in biomedical informatics, both from Stanford, and MBA from Harvard. I speak natively 3 languages, live carbon-neutral, am a 70.3 Ironman finisher, and have built a hospital in rural India serving 100,000 people.